Q-omics provides the consensus-scored MIR5696 profile across patient tissues and cancer cell-line models. MIR5696 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR5696 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, MIR5696 RNA expression shows 5,533 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, COAD, and STAD as cancer lineages where MIR5696 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5696 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5696 survival associations across molecular data types. MIR5696 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5696 RNA expression–survival associations across cancer types. High MIR5696 expression shows unfavorable associations in ESCA, STAD, ACC, SARC, COAD and LGG. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR5696 RNA expression.
This table summarizes MIR5696 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5696. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5696 shows lower tumor expression in COAD, LUSC and THCA. The COAD box plot shows higher MIR5696 RNA expression in normal versus tumor tissue (log2 FC = −0.196, t-test p = .041).
This table shows molecular features associated with MIR5696 in patient tissues and cancer cell lines. In patient samples, MIR5696 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
